Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Ends Bifeprunox For Schizophrenia Development Deal With Solvay

This article was originally published in The Pink Sheet Daily

Executive Summary

Wyeth decides drug candidate has inadequate commercial value for both companies to share, firm tells "The Pink Sheet" DAILY.

You may also be interested in...



Solvay Analyzing “Various Options” For Its Pharma Unit

Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.

Solvay Analyzing “Various Options” For Its Pharma Unit

Belgian firm, which co-markets TriLipix and TriCor with Abbott, confirms it is in discussions with third-parties.

Curis To Continue Focus On Oncology After Wyeth Ends Hedgehog Venture

Cambridge, Mass.-based Curis seeks a new partner to continue small molecule and protein hedgehog agonist development in cardiovascular/nervous system disorders.

Related Content

Topics

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel